Golden-Shell Pharmaceutical
Golden-Shell Pharmaceutical, also known as Jinke Chitin, is a leading player in the pharmaceutical industry, headquartered in China (CN). Established in 2001, the company has made significant strides in the development and production of chitin-based products, catering to both domestic and international markets. With a focus on biopharmaceuticals and innovative healthcare solutions, Golden-Shell Pharmaceutical stands out for its unique offerings, including high-quality chitosan and chitin derivatives. These products are renowned for their applications in drug delivery, wound healing, and dietary supplements, setting the company apart in a competitive landscape. Recognised for its commitment to research and development, Golden-Shell has achieved notable milestones, solidifying its market position as a trusted provider of advanced pharmaceutical solutions. The company continues to expand its operational reach, contributing to the global healthcare sector with its cutting-edge products and services.
DitchCarbon Score
How does Golden-Shell Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Golden-Shell Pharmaceutical's score of 0 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Golden-Shell Pharmaceutical's reported carbon emissions
Golden-Shell Pharmaceutical, headquartered in CN, currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing carbon emissions and setting ambitious targets to mitigate climate impact. As such, Golden-Shell Pharmaceutical may benefit from establishing clear commitments and measurable goals to enhance its sustainability profile and align with industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Golden-Shell Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
